Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can peppermint oil help stop heart disease before it starts?

NCT ID NCT07815899

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether peppermint oil supplements can improve heart health markers in adults with pre-metabolic syndrome, a condition where people have some risk factors for heart disease and diabetes but do not meet the full criteria for metabolic syndrome. The trial enrolls 40 adults aged 18 to 65 who are not taking medication for blood pressure, blood sugar, or cholesterol. Participants take peppermint oil or a placebo twice daily for a set period, and researchers measure changes in blood pressure, body fat, and other cardiometabolic parameters.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
peppermint oil
What this could lead to
If it works, peppermint oil could offer a low-cost, low-risk dietary option to help people with early heart risk factors before they develop full metabolic syndrome.
What could go wrong
This is a small, early-stage trial with 40 participants, so any benefits seen may not hold up in larger studies. Peppermint oil can cause heartburn or digestive upset in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2025

Finished

Sep 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Aged 18-65 years. Meet two of the five metabolic syndrome criteria. Not taking prescribed medication specifically intended to manage blood pressure, blood glucose or blood lipids. Able to complete written questionnaires independently. Able to provide informed consent. Exclusion Criteria: Diagnosed diabetes mellitus. Known cardiovascular disease or clinically significant cardiovascular comorbidity, including coronary heart disease, symptomatic heart failure, clinically significant arrhythmia, or a history of stroke or transient ischaemic attack within the previous six months. Known or suspected secondary hypertension, including renal, renovascular or endocrine causes. Known clinically significant renal impairment or severe hepatic disease. Evidence or history of hypertension-related target-organ damage requiring specialist management. Pregnant or lactating. Allergy or known intolerance to peppermint or any ingredient contained in the intervention or placebo. Habitual consumption of peppermint products. Regular consumption of antioxidant or other dietary supplements likely to influence cardiometabolic outcomes. Body mass index greater than 40.0 kg/m². Current enrolment in another clinical trial or use of another intervention or therapy likely to influence the study outcomes. Any condition likely to compromise informed consent, protocol compliance or outcome assessment, including severe psychiatric illness, cognitive impairment, or active substance or alcohol misuse.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Lancashire

    Preston, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.